Last reviewed · How we verify

Serazide (BENSERAZIDE)

FDA-approved active Small molecule ✓ Verified May 2026 Quality 20/100

Serazide (generic name: BENSERAZIDE) is a drug. It is currently FDA-approved.

Serazide is a small molecule inhibitor of the enzyme aromatic-L-amino-acid decarboxylase. It is used as a DOPA decarboxylase inhibitor, and its clinical trials have studied various conditions including hormonal changes, menstrual cycle, Parkinson disease, aphasia, and beta thalassemia intermedia.

At a glance

Generic nameBENSERAZIDE
TargetSUMO-activating enzyme, Hexokinase-2, Aromatic-L-amino-acid decarboxylase
ModalitySmall molecule
Therapeutic areaOther
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Serazide

What is Serazide?

Serazide (BENSERAZIDE) is a Small molecule drug.

What is the generic name of Serazide?

BENSERAZIDE is the generic (nonproprietary) name of Serazide.

What development phase is Serazide in?

Serazide is FDA-approved (marketed).

What does Serazide target?

Serazide targets SUMO-activating enzyme, Hexokinase-2, Aromatic-L-amino-acid decarboxylase.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing